Matinas BioPharma to Hold Virtual R&D Day on June 17, 2021

Rhea-AI Summary

Matinas BioPharma (MTNB) has announced a virtual R&D Day on June 17, 2021, at 8:30 a.m. ET, highlighting its lipid nanocrystal (LNC) delivery platform and pipeline programs. Key leaders, including Professors David Boulware and Peter Pappas, will provide clinical insights. The company is developing products like MAT2203 for cryptococcal meningitis and MAT2501 for nontuberculous mycobacterial lung infections, backed by funding from the Cystic Fibrosis Foundation. LYPDISO™ shows promising results in triglyceride management against Vascepa. A live Q&A session will follow the presentations.

Positive

• Announcement of a virtual R&D Day showcasing technological advancements and pipeline programs.
• Development of MAT2203, currently in Phase 2 trials for treating cryptococcal meningitis.
• Funding of up to $3.75 million from the Cystic Fibrosis Foundation for MAT2501's development.
• Promising clinical data for LYPDISO™, indicating a superior cardioprotective effect compared to Vascepa.

Negative

• None.

Matinas will highlight progress across its lipid nanocrystal (LNC) delivery platform and associated pipeline programs

David R. Boulware, M.D., MPH, Professor of Medicine, Infectious Disease and International Medicine, Univ. of Minnesota, and Peter G. Pappas, M.D., Professor of Medicine, Medicine/Infectious Diseases Department, Univ. of Alabama at Birmingham, to provide clinical perspectives

BEDMINSTER, N.J., May 20, 2021 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a biopharmaceutical company focused on improving the intracellular delivery of critical therapeutics through its paradigm-changing lipid nanocrystal (LNC) delivery platform, today announced it will host a virtual R&D Day on Thursday, June 17, beginning at 8:30 a.m. During the event, members of the Matinas management team will discuss the Company’s key pipeline programs and its proprietary, highly differentiated technology that solves complex challenges relating to the safe and effective intracellular delivery of both small and large molecules. In addition, two internationally regarded clinical key opinion leaders will provide their perspectives.

Pre-registration for the webcast is available HERE and on the Investors section of the Company’s website at www.matinasbiopharma.com. An interactive online Q&A session with the presenters will be available during the event. Questions can also be submitted via email to brandon.weiner@westwicke.com in advance and prior to the event, or during the event itself.

R&D Day Information

Date: Thursday, June 17, 2021
Time: 8:30 a.m. – 10:15 a.m. ET

Presenters

• David R. Boulware, M.D., MPH, Professor of Medicine, Infectious Disease & International Medicine, Department of Medicine, University of Minnesota
• Peter G. Pappas, M.D., Professor of Medicine, Medicine/Infectious Diseases Department, University of Alabama at Birmingham
• Jerome D. Jabbour, Chief Executive Officer, Matinas BioPharma
• James J. Ferguson, M.D., FACC, FAHA, Chief Medical Officer, Matinas BioPharma
• Theresa Matkovits, Ph.D., Chief Development Officer, Matinas BioPharma
• Raphael J. Mannino, Ph.D., Chief Scientific Officer, Matinas BioPharma
• Hui Liu, Ph.D., Chief Technology Officer, Matinas BioPharma
  

A live webcast of the R&D Day can be accessed through the Investors section of the Company’s website (www.matinasbiopharma.com). Please log in approximately 10 minutes prior to the scheduled start time. An archived webcast replay will be made available on the Company’s website.

About Matinas BioPharma

Matinas BioPharma is a biopharmaceutical company focused on improving the intracellular delivery of critical therapeutics through its paradigm-changing lipid nanocrystal (LNC) delivery platform. Company leadership has a deep history and knowledge of drug development and is supported by a world-class team of scientific advisors.

Matinas is developing a portfolio of products based upon its proprietary LNC drug delivery platform, which can solve complex challenges relating to the safe and effective intracellular delivery of both small and larger, more complex molecules.

MAT2203 is an oral, LNC formulation of the well-known, but highly toxic, antifungal medicine amphotericin B, primarily used to treat serious invasive fungal infections. MAT2203 is currently in a Phase 2 open-label, sequential randomized trial (EnACT) in HIV-infected patients with cryptococcal meningitis. EnACT is currently enrolling patients in its second cohort, with the next DSMB evaluation of safety and efficacy data anticipated to occur in the third quarter of 2021.

MAT2501 is an oral, LNC formulation of the broad-spectrum aminoglycoside antibiotic medicine amikacin, primarily used to treat chronic and acute bacterial infections. The Company has been awarded up to $3.75 million from the Cystic Fibrosis Foundation (CFF) to support development of MAT2501 toward an indication to treat nontuberculous mycobacterial (NTM) lung disease, including infections in patients with cystic fibrosis (CF).

LYPDISO™, the Company’s product candidate intended for the treatment of cardiovascular and metabolic conditions, is a prescription-only omega-3 fatty acid-based composition, comprised primarily of EPA and DPA. Matinas recently announced data from the ENHANCE-IT study, a head-to-head crossover study evaluating LYPDISO vs. Vascepa in patients with elevated triglycerides. These data demonstrated superior levels of eicosapentaenoic acid (EPA) in the blood with LYPDISO, and support the potential superior cardioprotective effect of LYPDISO vs. Vascepa. The Company has initiated a process to identity and secure a potential partner to continue development of LYPDISO toward a cardiovascular outcomes indication.

Forward-Looking Statements

This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including those relating to the LNC platform delivery technology, the Company’s strategic focus and the future development of its product candidates, including MAT2203, MAT2501 and LYPDISO, the anticipated timing of regulatory submissions, the anticipated timing of clinical studies, the anticipated timing of regulatory interactions, the Company’s ability to identify and pursue development and partnership opportunities for its products or platform delivery technology on favorable terms, if at all, and the ability to obtain required regulatory approval and other statements that are predictive in nature, that depend upon or refer to future events or conditions. All statements other than statements of historical fact are statements that could be forward-looking statements. Forward-looking statements include words such as "expects," "anticipates," "intends," "plans," "could," "believes," "estimates" and similar expressions. These statements involve known and unknown risks, uncertainties and other factors which may cause actual results to be materially different from any future results expressed or implied by the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, our ability to obtain additional capital to meet our liquidity needs on acceptable terms, or at all, including the additional capital which will be necessary to complete the clinical trials of our product candidates; our ability to successfully complete research and further development and commercialization of our product candidates; the uncertainties inherent in clinical testing; the timing, cost and uncertainty of obtaining regulatory approvals; our ability to protect the Company’s intellectual property; the loss of any executive officers or key personnel or consultants; competition; changes in the regulatory landscape or the imposition of regulations that affect the Company’s products; and the other factors listed under "Risk Factors" in our filings with the SEC, including Forms 10-K, 10-Q and 8-K. Investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this release. Except as may be required by law, the Company does not undertake any obligation to release publicly any revisions to such forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. Matinas BioPharma’s product candidates are all in a development stage and are not available for sale or use.

Investor and Media Contacts Peter Vozzo Westwicke/ICR 443-213-0505 peter.vozzo@westwicke.com

FAQ

What is the date and time of Matinas BioPharma's R&D Day?

Matinas BioPharma's R&D Day is scheduled for June 17, 2021, at 8:30 a.m. ET.

What products are being developed by Matinas BioPharma?

Matinas BioPharma is developing MAT2203 for cryptococcal meningitis, MAT2501 for nontuberculous mycobacterial lung infections, and LYPDISO™ for cardiovascular conditions.

Who are the key presenters at the R&D Day?

Key presenters include David R. Boulware, M.D., MPH, and Peter G. Pappas, M.D., along with Matinas leadership.

What is the significance of the funding received by Matinas BioPharma?

The funding of up to $3.75 million from the Cystic Fibrosis Foundation supports the development of MAT2501 for treating nontuberculous mycobacterial lung disease.

What are the clinical results for LYPDISO™?

LYPDISO™ has demonstrated superior levels of eicosapentaenoic acid (EPA) in the blood compared to Vascepa, suggesting a better cardioprotective effect.